MLYS insider buying and SEC filings, explained
Mineralys Therapeutics, Inc. · CIK 1933414
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$8.8M
Insiders who bought
1
Sold (not marked 10b5-1)
$60.8M
Planned sales (10b5-1)
$24.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 30, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 75,000 shares at about $25.46 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 12% to 528,621 shares. | SEC filing Filed Oct 2, 2026, 5:53 PM ET |
| Sep 22, 2026 | Sale | Brian Taylor Slingsby (Director) sold 104,320 shares indirectly at about $28.81 ($3.0M). Indirect holdings down 1% to 7,805,718 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 24, 2026 |
| Sep 21, 2026 | Planned (10b5-1) | Eric Warren (Chief Commercial Officer) sold 7,438 shares at about $28.12 ($209K), marked as a 10b5-1 plan trade. Holdings down 16% to 38,400 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Daphne Karydas (Director) sold 3,000 shares at $28.58 ($86K), marked as a 10b5-1 plan trade. Holdings down 33% to 6,200 shares. | SEC filing Filed Sep 17, 2026 |
| Aug 21, 2026 | Planned (10b5-1) | Eric Warren (Chief Commercial Officer) sold 7,437 shares at about $25.98 ($193K), marked as a 10b5-1 plan trade. Holdings down 16% to 38,400 shares. | SEC filing Filed Aug 25, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 2,170 shares at $27.09 ($59K), marked as a 10b5-1 plan trade. Holdings down 4% to 51,384 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 21, 2026 | Planned (10b5-1) | Eric Warren (Chief Commercial Officer) sold 7,438 shares at about $26.87 ($200K), marked as a 10b5-1 plan trade. Holdings down 16% to 38,400 shares. | SEC filing Filed Jul 23, 2026 |
| Jul 17, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 416 shares at $26.53 ($11K), marked as a 10b5-1 plan trade. Holdings down 1% to 51,384 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 10,700 shares at about $27.24 ($291K), marked as a 10b5-1 plan trade. Holdings down 2% to 603,621 shares. | SEC filing Filed Jul 15, 2026 |
| Jul 13–15, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 20,407 shares between Jul 13 and Jul 15 at about $27.28 ($557K), marked as a 10b5-1 plan trade. Holdings down 28% to 51,384 shares. | SEC filing Filed Jul 15, 2026 |
| Jul 9, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 2,171 shares at $30.30 ($66K), marked as a 10b5-1 plan trade. Holdings down 4% to 57,733 shares. | SEC filing Filed Jul 10, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 75,000 shares at about $26.14 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 11% to 614,321 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Eric Warren (Chief Commercial Officer) sold 104,124 shares at about $25.90 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 73% to 38,400 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Daphne Karydas (Director) sold 3,000 shares at $25.00 ($75K), marked as a 10b5-1 plan trade. Holdings down 33% to 6,200 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 15–17, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 14,474 shares between Jun 15 and Jun 17 at about $24.19 ($350K), marked as a 10b5-1 plan trade. Holdings down 20% to 57,095 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 10–12, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 8,519 shares between Jun 10 and Jun 12 at about $24.20 ($206K), marked as a 10b5-1 plan trade. Holdings down 12% to 63,443 shares. | SEC filing Filed Jun 12, 2026 |
| May 18, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 417 shares at $27.55 ($11K), marked as a 10b5-1 plan trade. Holdings down 1% to 63,443 shares. | SEC filing Filed May 19, 2026 |
| May 11–13, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 22,575 shares between May 11 and May 13 at about $28.91 ($653K), marked as a 10b5-1 plan trade. Holdings down 26% to 63,443 shares. | SEC filing Filed May 13, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 416 shares at $31.33 ($13K), marked as a 10b5-1 plan trade. Holdings down 1% to 69,792 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 13–15, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 20,406 shares between Apr 13 and Apr 15 at about $26.89 ($549K), marked as a 10b5-1 plan trade. Holdings down 23% to 69,792 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 13, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 15,730 shares at about $26.83 ($422K), marked as a 10b5-1 plan trade. Holdings down 2% to 689,321 shares. | SEC filing Filed Apr 15, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 2,170 shares at $27.38 ($59K), marked as a 10b5-1 plan trade. Holdings down 3% to 76,140 shares. | SEC filing Filed Apr 13, 2026 |
| Mar 31, 2026 | Planned (10b5-1) | Daphne Karydas (Director) sold 3,000 shares at $25.00 ($75K), marked as a 10b5-1 plan trade. Holdings down 33% to 6,200 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 31, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 75,000 shares at about $26.27 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 10% to 705,051 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 27–30, 2026 | Purchase (code P) | Peter Kolchinsky (Director) bought 369,000 shares indirectly between Mar 27 and Mar 30 at about $23.75 ($8.8M), reported as a purchase (code P). Indirect holdings up 7% to 5,825,521 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Mar 31, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 417 shares at $25.65 ($11K), marked as a 10b5-1 plan trade. Holdings down 1% to 76,140 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 12–13, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 20,406 shares between Mar 12 and Mar 13 at about $26.61 ($543K), marked as a 10b5-1 plan trade. Holdings down 21% to 76,140 shares. | SEC filing Filed Mar 16, 2026 |
| Mar 9, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 2,171 shares at $26.84 ($58K), marked as a 10b5-1 plan trade. Holdings down 3% to 82,489 shares. | SEC filing Filed Mar 10, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 417 shares at $27.59 ($12K), marked as a 10b5-1 plan trade. Holdings down 1% to 44,089 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 12–13, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 20,404 shares between Feb 12 and Feb 13 at about $27.93 ($570K), marked as a 10b5-1 plan trade. Holdings down 32% to 44,089 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 9, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 2,171 shares at $30.21 ($66K), marked as a 10b5-1 plan trade. Holdings down 4% to 50,437 shares. | SEC filing Filed Feb 11, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 416 shares at $32.10 ($13K), marked as a 10b5-1 plan trade. Holdings down 1% to 50,437 shares. | SEC filing Filed Jan 20, 2026 |
| Jan 13–14, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 19,076 shares between Jan 13 and Jan 14 at about $32.67 ($623K), marked as a 10b5-1 plan trade. Holdings down 27% to 50,437 shares. | SEC filing Filed Jan 15, 2026 |
| Jan 12, 2026 | Planned (10b5-1) | Adam Scott Levy (CFO) sold 10,758 shares at about $32.14 ($346K), marked as a 10b5-1 plan trade. Holdings down 55% to 8,638 shares. | SEC filing Filed Jan 13, 2026 |
| Jan 12, 2026 | Planned (10b5-1) | Jon Congleton (CEO and Director) sold 16,236 shares at about $32.62 ($530K), marked as a 10b5-1 plan trade. Holdings down 2% to 639,151 shares. | SEC filing Filed Jan 13, 2026 |
| Jan 9–12, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 8,518 shares between Jan 9 and Jan 12 at about $32.56 ($277K), marked as a 10b5-1 plan trade. Holdings down 12% to 61,804 shares. | SEC filing Filed Jan 13, 2026 |
| Jan 2–5, 2026 | Planned (10b5-1) | David Malcom Rodman (Chief Medical Officer) sold 262,752 shares between Jan 2 and Jan 5 at about $35.25 ($9.3M), marked as a 10b5-1 plan trade. Holdings down 81% to 61,804 shares. | SEC filing Filed Jan 6, 2026 |
| Nov 20, 2025 | Sale | Brian Taylor Slingsby (Director and 10% owner) sold 1,000,000 shares indirectly at $43.35 ($43.4M). Indirect holdings down 11% to 7,903,838 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Nov 21, 2025 |
| Nov 11, 2025 | Sale | Adam Scott Levy (CFO) sold 119,524 shares at about $44.87 ($5.4M). Holdings down 86% to 19,396 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
| Nov 11, 2025 | Sale | Jon Congleton (CEO and Director) sold 200,000 shares at about $45.44 ($9.1M). Holdings down 24% to 631,305 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
47 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MLYS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.